These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23563102)

  • 1. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery.
    Tewes F; Paluch KJ; Tajber L; Gulati K; Kalantri D; Ehrhardt C; Healy AM
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):604-13. PubMed ID: 23563102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
    Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
    Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
    Bur M; Huwer H; Muys L; Lehr CM
    J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide.
    Dufour G; Bigazzi W; Wong N; Boschini F; de Tullio P; Piel G; Cataldo D; Evrard B
    Int J Pharm; 2015 Nov; 495(2):869-78. PubMed ID: 26410753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV; Jain RR; Bannalikar AS; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of mucus and its impact within in vitro setups for inhaled drugs and formulations: Identifying the limits of simple vs. complex methodologies when studying drug dissolution and permeability.
    Radivojev S; Kargl L; Pinto JT; Swedrowska M; Malmlöf M; Meindl C; Forbes B; Gerde P; Paudel A; Fröhlich E
    Int J Pharm; 2024 Aug; 661():124455. PubMed ID: 38986963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglicate.
    Nolan LM; Li J; Tajber L; Corrigan OI; Healy AM
    Int J Pharm; 2011 Feb; 405(1-2):36-46. PubMed ID: 21129460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation.
    Amaro MI; Tewes F; Gobbo O; Tajber L; Corrigan OI; Ehrhardt C; Healy AM
    Int J Pharm; 2015 Apr; 483(1-2):6-18. PubMed ID: 25660067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery.
    Ogáin ON; Li J; Tajber L; Corrigan OI; Healy AM
    Int J Pharm; 2011 Feb; 405(1-2):23-35. PubMed ID: 21129458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat.
    Ren YC; Wang L; He HB; Tang X
    J Pharm Sci; 2009 May; 98(5):1797-803. PubMed ID: 18837427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid lipid budesonide microparticles for controlled release inhalation therapy.
    Mezzena M; Scalia S; Young PM; Traini D
    AAPS J; 2009 Dec; 11(4):771-8. PubMed ID: 19908147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy.
    Leng D; Kissi EO; Löbmann K; Thanki K; Fattal E; Rades T; Foged C; Yang M
    AAPS PharmSciTech; 2019 Mar; 20(3):137. PubMed ID: 30847607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?
    Ong HX; Traini D; Loo CY; Sarkissian L; Lauretani G; Scalia S; Young PM
    Eur J Pharm Biopharm; 2015 Jun; 93():320-7. PubMed ID: 25930239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of particle diameter on aerosolization performance and release of budesonide loaded mesoporous silica particles.
    van der Zwaan I; Pilkington GA; Frenning G; Ekström M; Valetti S; Pitcairn GR; Feiler A
    Eur J Pharm Sci; 2024 Sep; 200():106828. PubMed ID: 38862047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
    Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
    Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
    Akdag Cayli Y; Sahin S; Buttini F; Balducci AG; Montanari S; Vural I; Oner L
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1378-1389. PubMed ID: 28420285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of drug dissolution and uptake from low-density DPI formulations in an impactor-integrated cell culture model.
    Šimková K; Thormann U; Imanidis G
    Eur J Pharm Biopharm; 2020 Oct; 155():12-21. PubMed ID: 32717388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy.
    Lee SH; Heng D; Teo JWP; Toh FKY; Tan RBH
    Int J Pharm; 2019 Dec; 572():118740. PubMed ID: 31648015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
    Devrim B; Bozkır A; Canefe K
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.